Human Coagulation Factor VIII
Hemophilia A
Key Facts
About Shanghai RAAS Blood Products
Shanghai RAAS Blood Products is a critical enterprise in China's national biopharmaceutical strategy, focusing on ensuring the supply and safety of plasma-derived therapies. The company operates numerous plasma collection stations and has a vertically integrated manufacturing platform, positioning it as a dominant force in a market with significant barriers to entry. Its strategic direction involves expanding its plasma fractionation capacity, advancing its recombinant protein pipeline, and leveraging its scale to meet growing domestic demand for essential blood products.
View full company profileAbout Hualan Biological Engineering
Hualan Biological Engineering is a prominent, vertically integrated vaccine and blood product manufacturer in China, with a significant market share in influenza vaccines. The company leverages its established production capabilities and extensive distribution network to serve the domestic public health market. Its strategic focus includes expanding its vaccine portfolio, advancing its plasma fractionation business, and pursuing international market opportunities. As a publicly traded entity, it plays a key role in China's national immunization programs and biosecurity strategy.
View full company profileOther Hemophilia A Drugs
| Drug | Company | Phase |
|---|---|---|
| Hemlibra (emicizumab) | Chugai Pharmaceutical | Approved |
| Factor VIII Products | CSL | Commercial |
| Gene Therapy | BioMarin Pharmaceutical | Commercial |
| Recombinant Coagulation Factor VIII | Shanghai RAAS Blood Products | Phase 3 |
| Factor VIII | Tiantan Bio | Approved |
| Recombinant Factor VIII | Hualan Biological Engineering | Pre-clinical |
| Giroctocogene fitelparvovec (SB-525) | Sangamo Therapeutics | Phase 3 |